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Around 400 million people worldwide suffer from diabetes mellitus. The major pathological event for Type 1 diabetes and
advanced Type 2 diabetes is loss or impairment of insulin-secreting β cells of the pancreas. For the past 100 years, daily insulin
injection has served as a life-saving treatment for these patients. However, insulin injection often cannot achieve full glucose
control, and over time poor glucose control leads to severe complications and mortality. As an alternative treatment, islet
transplantation has been demonstrated to effectively maintain glucose homeostasis in diabetic patients, but its wide application is
limited by the scarcity of donated islets. Therefore, it is important to define new strategies to obtain functional human β cells for
transplantation therapies. Here, we summarize recent progress towards the production of β cells in vitro from pluripotent stem
cells or somatic cell types including α cells, pancreatic exocrine cells, gastrointestinal stem cells, fibroblasts and hepatocytes. We
also discuss novel methods for optimizing β cell transplantation and maintenance in vivo. From our perspective, the future of β
cell replacement therapy is very promising although it is still challenging to control differentiation of β cells in vitro and to protect
these cells from autoimmune attack in Type 1 diabetic patients. Overall, tremendous progress has been made in understanding β
cell differentiation and producing functional β cells with different methods. In the coming years, we believe more clinical trials
will be launched to move these technologies towards treatments to benefit diabetic patients.
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INTRODUCTION
Diabetes mellitus is a metabolic disease that affects nearly
400 million people worldwide. Diabetic patients suffer from
hyperglycemia due to a failure of glucose regulation (Shi
and Hu, 2014) and are subject to a variety of complications
such as retinopathy, kidney disease, cardiovascular disease,
diabetic foot ulcers, diabetic enteropathy, and neuropathy
(D’Addio et al., 2015). The islets of Langerhans, which
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amount to 1% of the human pancreas, are clusters of en-
docrine cells that are responsible for closely controlling
blood glucose levels. There are four major cell types in the
islet: α cells, β cells, δ cells, and pancreatic polypeptide (PP)
cells. Of these, β cells secret the glucose-lowing hormone
insulin in response to high blood glucose, while α cells
secrete glucose-elevating hormone glucagon when blood
glucose is low.
Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) are the
two major types of diabetes. T1D is characterized by β cell
destruction by the immune system, thus causing insufficient
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insulin production and increased blood glucose levels. T2D
usually begins with peripheral insulin resistance, which pro-
gresses to persistent high blood glucose. In the advanced
stages of T2D, β cells can become dysfunctional, and may
eventually be lost.
Insulin replacement therapy has been utilized for almost
100 years for T1D (Bruin et al., 2015b). However, even
daily injections of insulin may not control blood glucose
perfectly, sometimes resulting in hypoglycemia, ketosis and
coma (DCCT/EDIC Research Group et al., 2009). T2D is
commonly controlled by small-molecule drugs to promote
β-cell function, to enhance insulin secretion and insulin
sensitivity, and to facilitate glucose utilization. For advanced
T2D patients, insulin therapy also becomes obligatory. Over-
all, it is difficult to achieve complete glucose control with
insulin therapy for T1D and advanced T2D. Therefore, it is
crucial to find new strategies to reverse hyperglycemia and
alleviate the many debilitating complications of diabetes.
Insulin independence therapy was first performed in
2000, when pancreatic islets isolated from human cadavers
were transplanted into the liver of Type 1 Diabetic patients
(Shapiro et al., 2000). Since then, more than 750 islet trans-
plantations have been performed. Among the recipients, 44%
could maintain normal blood glucose level without exoge-
nous insulin supply for an extended period of time (Rekittke
et al., 2016). However, widespread adoption of islet trans-
plantation is not possible due to the shortage of cadaveric
islet donors (Bellin et al., 2012). In response, many research
groups have been developing novel technologies aimed at
generating new functional β cells that can be transplanted.
These strategies have explored use of different cells and
tissues, including pluripotent stem cells and somatic cells, to
generate functional β cells by treatment with genetic factors,
small molecules, and growth factors (Figure 1). Furthermore,
induction of β-cell replication may potentially generate more
β cells endogenously (Annes et al., 2012; Dor and Melton,
2004; Shen et al., 2013). Meanwhile, continuous efforts
have been made to develop novel techniques to promote
β-cell graft survival and maturation in vivo. Encapsulation
technologies have also been improved to better protect β
cells from immune attack. Here we summarize the recent
advances in β cell generation and transplantation.
GENERATING β CELLS FROM PLURIPOTENT
STEM CELLS IN VITRO
In T1D patients, the majority of β cells are lost to an autoim-
mune attack. In advanced T2D patients, the number of β
cells is often lower than comparable non-diabetic individu-
als (Rahier et al., 2008), and the function of the remaining β
cells is attenuated (Costes et al., 2013). Insulin injections and
drug treatments only act to reverse hyperglycemia, and do not
increase the number of β cells. To tackle diabetes in diabetics
of both types, perhaps the best strategy is to replenish the β
cell mass. But how can replacement β cells be made?
One promising strategy is to derive β cells from pluripo-
tent stem cells. In the past 20 years, there have been several
landmark achievements in stem cell derivation, differentia-
tion, and reprogramming (Chari and Mao, 2016; Shiba et al.,
2012). In 1998 Thomson et al. developed a method to suc-
cessfully culture human embryonic stem cells (hESCs) which
can  generate  all  three germ layers and  the  associated cell
Figure 1   Strategies to generate functional β cells. This diagram summarizes the different strategies used to generate functional insulin-secreting cells in animal
models or with human cells. Directed differentiation using growth factors and small molecules can induce pluripotent stem cells (dark blue) into endoderm (yel-
low), posterior foregut (green), pancreatic progenitors (dark green) and β cells (red). Reprogramming technologies have also been developed to generate β-like
cells from multiple somatic cell sources, including pancreatic α cells, pancreatic acinar cells, hepatocytes, gut organoids, antral stomach cells and fibroblasts.
Somatic cell reprogramming to β cells requires different combinations of transcription factors and small molecules, depending upon the starting cell type.
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types (Thomson et al., 1998). In 2006 Takahashi and Ya-
manaka discovered the method to generate induced pluripo-
tent stem cells (iPSCs) frommurine fibroblasts with four tran-
scriptional factors (Takahashi and Yamanaka, 2006). Since
then, research on iPSCs generation from different types of
human cells has been advancing at a remarkable pace (Chari
and Mao, 2016; Takahashi and Yamanaka, 2016). In addi-
tion, a scalable system for producing functional pancreatic
progenitors from human ESCs has been well-established and
shown to reverse hyperglycemia after transplantation in mice
(Rezania et al., 2012; Schulz et al., 2012). Therefore, hu-
man pluripotent stem cells, with their vast capacity for ex-
pansion and their ability to differentiate, are a very promising
cell source for the production of new β cells.
It has proved challenging to produce mature β cells in
vitro. Mature β cells respond to increased glucose by secret-
ing insulin, and turn off insulin secretion rapidly at lower
glucose concentrations to avoid hypoglycemia. In the past
decade, most differentiation protocols only managed to
produce pancreatic endocrine progenitor cells or endocrine
cells that co-express glucagon and insulin, but failed to
generate mature β cells in vitro (Bruin et al., 2014). It is
very difficult to make mature NKX6.1+/MafA+ β cells that
only secrete insulin without producing glucagon and somato-
statin (Bruin et al., 2013). In 1997 it was shown that when
human fetal islet-like cell clusters were transplanted into
mice, they matured into glucose-responsive insulin-secreting
cells, which indicated that the pancreatic progenitors could
differentiate further in vivo (Hayek and Beattie, 1997). In
2006, D’Amour et al. firstly differentiated human ESCs into
hormone-expressing endocrine cells with limited glucose re-
sponsiveness, a phenotype similar to fetal β cells (D’Amour
et al., 2006). Then Kroon et al. successfully generated
pancreatic endoderm from human ESCs that could be further
differentiated into glucose-responsive insulin-secreting cells
in vivo (Kroon et al., 2008). These cells had therapeutic po-
tential because transplantation of these cells protected mice
from streptozotocin (STZ)-induced hyperglycemia. In 2011,
Kelly et al. further purified hESC-derived pancreatic cell
cultures by FACS (fluorescence activated cell sorting) using
CD142 as a marker. It was observed that CD142-enriched
pancreatic endoderm cells were PDX1+/NKX6.1+/PTF1A+
pancreatic progenitors, which could generate pancreatic
lineages in vivo (Kelly et al., 2011).
Significant advances have recently been made with regard
to generating mature β-like cells from human pluripotent
stem cells (Pagliuca et al., 2014). In 2014, Rezania et al.
optimized a previously published six-stage protocol to make
immature β cells and built a seven-stage in vitro differen-
tiation protocol for mature β cells (Rezania et al., 2014).
They first enhanced the production of PDX1+/NKX6.1+
pancreatic progenitors with low expression level of NGN3
by adding the antioxidant vitamin C, which prevented the
formation of polyhormonal cells induced by early expression
of NGN3. The increase of glucose concentration from 10 to
20 mmol L–1 and the addition of ALK5 inhibitor, BMP recep-
tor inhibitor and thyroid hormone (T3) to air-liquid interface
(ALI) cultures enabled the differentiation of the pancreatic
progenitors into pancreatic endocrine precursors. Further
exposure to a Notch signaling pathway inhibitor shunted the
cells toward immature β cells (PDX1+/NKX6.1+/NEUROD+)
that still lack expression of MafA. In a subsequent screening
of small molecules and growth factors, an inhibitor of the
tyrosine kinase receptor AXL was found to induce MafA
expression, producing the so-called mature β cells derived
from hESC. These cells were shown to possess functional
similarities to human β cells in terms of insulin content, glu-
cose-stimulated human c-peptide secretion and ultrastructure
of insulin granules, and they successfully reversed STZ-in-
duced diabetes less than six weeks after transplantation under
kidney capsule in immune-deficient mice. However, the
calcium dynamics and insulin secretory kinetics were limited
in the hESC-derived β cells compared to human islets, and
the long-term function and safety of these cells in vivo are
still not clear.
Pagliuca et al. reported a similar differentiation protocol to
generate β cells in vitro from hESCs (Pagliuca et al., 2014).
They applied a suspension-based culture system in contrast to
the more traditional monolayer culture used in Rezania’s pro-
tocol. Pagliuca’s protocol added keratinocyte growth factor
(KGF) from the definitive endoderm stage to the pancreatic
progenitor stage. They also added ALK5 inhibitor, γ-secre-
tase inhibitor, and heparin to induce pancreatic progenitor cell
differentiation into pancreatic endocrine cells. Additionally,
the epidermal growth factor receptor ligand betacellulin was
added to promote and maintain the NKX6.1 expression level
in the endocrine cells. Pagliuca et al. transplanted the stem
cell-derived β cells (SC-β cells) under the kidney capsule and
found that, two weeks after transplantation, eight out of 12
of mice had higher human insulin levels after a glucose chal-
lenge, which demonstrated that the in vivo function of SC-β
cells closely resemble human β cells. Further, the SC-β cells
secreted higher levels of human insulin in response to three
consecutive high glucose challenges, showing the potential
of these cells to consistently function after transplantation.
By measuring intracellular calcium flux, Pagliuca et al. also
demonstrated that the SC-β cells could respond to two to three
sequential challenges, and they could flux calcium similarly
to primary human islet cells. Despite these significant ad-
vances, the long-term survival and function of these cells in
vivo remain to be fully determined.
The two studies discussed above opened the possibility for
using hESC-derived β cells to treat diabetes, which represents
a significant step toward making a clinical impact with stem
cell biology (Pagliuca et al., 2014). However, a report that
~50% of the mice formed sporadic mesoderm after transplan-
Lu, J., et al.   Sci China Life Sci   March (2017)  Vol. 60  No. 3 241
tation with these iPSCs-derived β cells raises a cautionary
note (Bruin et al., 2013). How well iPSCs can be differen-
tiated into functional β cells remains uncertain. One poten-
tial issue is that the epigenetic memory of iPSCs may affect
their differentiation into β cells. Bar-Nur et al. demonstrated
that unlike other iPSCs, β cell-derived iPSCsmaintained open
chromatin structure at key β cell genes and possessed in-
creased capacity to differentiate into β cells compared with
hESCs and isogenic non-β cell-derived iPSCs (Bar-Nur et al.,
2011). Thus, it is crucial to choose the right type of iPSCs for
differentiation from the outset. Xie et al. used RNA-seq and
ChIP-seq to further investigate the chromatin structure during
hESC differentiation to pancreatic progenitors and then to en-
docrine cells in vivo (Xie et al., 2013). It was demonstrated
that the chromatin of β cell genes is differently remodeled
during β cell differentiation in vitro. By systematic labeling
of key developmental genes at different differentiation stages,
Liu et al. identified a novel surface protein, SUSD2 (Sushi
domain containing 2) as a marker that permitted the enrich-
ment of pancreatic endocrine progenitor cells in hESC-de-
rived pancreatic cell cultures and in the developing human
pancreas (Liu et al., 2014). Transplantation of SUSD2-en-
riched cell populations could provide a better way to get ma-
ture β cells after transplantation in mice (Liu et al., 2014).
Thus from the clinical perspective, optimization of these pub-
lished protocols is necessary.
In the past years, significant advances have been made to
regulate pancreatic differentiation of human pluripotent stem
cells (hPSCs) by modulating signal pathways, including
retinoic acid, Wnt, bone morphogenic protein (BMP), fibrob-
last growth factor (FGF), Notch, transforming growth factor
β (TGF-β) and sonic hedgehog (SHH) signaling pathways
(Nostro and Keller, 2012; Nostro et al., 2011). Nostro et
al. demonstrated that the combination of epidermal growth
factor (EGF) and nicotinamide signaling induced the devel-
opment of NKX6.1+ progenitors from hPSCs. The induced
NKX6.1+ progenitors were capable of differentiating into
insulin-secreting cells after transplantation into immunod-
eficient mice (Nostro et al., 2015). Russ et al. discovered
that BMP inhibition resulted in precocious induction of
endocrine differentiation in PDX1+ pancreatic progenitors,
which generated non-functional poly-hormonal cells, and
omission of BMP inhibitors could prevent precocious en-
docrine formation and effectively generate functional human
β-like cells (Russ et al., 2015). Precisely, dynamic temporal
regulation of TGF-β signaling is required for differentiation
of hESC into β cells because TGF-β ligands strongly inhibit
endocrine differentiation from progenitors, although these
TGF-β ligands significantly induce pancreatic progenitors
formation (Guo et al., 2013). Thus TGF-β ligand treatment
followed by TGF-β receptor antagonist addition can increase
insulin-producing cells in pancreatic differentiation in vitro
(Guo et al., 2013). Altogether, optimal stage-specific manip-
ulation of these signaling pathways is necessary for effective
generation of functional β cells from hPSC.
REPROGRAMMING SOMATIC CELLS INTO β
CELLS
Pluripotent stem cells are not the only source to make β cells.
In recent years, direct reprogramming (also known as trans-
differentiation, or direct lineage conversion) of different so-
matic cell types to β cells has shown great promise.
α to β cell reprogramming
Glucagon-secreting α cells share a close lineage relationship
with β cells. It has been shown that α cells harbor bivalent
chromatin signatures at β cell-specific genes, and under ex-
perimental conditions where most of the β cells are destroyed
by diphtheria toxin-mediated ablation, mouse α cells can gen-
erate insulin+ cells (Thorel et al., 2010). It is unclear, how-
ever, as to how closely the new β cells resemble endogenous
β cells in terms of their molecular characteristics and func-
tion. In addition, loss of β cells by other methods, such as
streptozotocin treatment, does not elicit this conversion event.
Overall, the mechanism of this conversion and whether it oc-
curs under physiological conditions remain unclear.
PAX4 was shown to promote differentiation of mouse pan-
creatic progenitor cells into α cells and subsequently to β cells
(Collombat et al., 2009). However, Chen et al. argued that
PAX4 expression didn’t induce significant α to β cell con-
version (Chen et al., 2015). Thus it is still debatable as to
whether PAX4 alone can promote α to β cell reprogramming.
In 2011, Yang et al. found that forced expression of PDX1
in the NGN3+ endocrine progenitor stage could facilitate α
to β cell conversion (Yang et al., 2011). Another study re-
vealed that inactivation of Arx in pancreatic α cells is suffi-
cient to promote the conversion of adult α cells into β-like
cells (Courtney et al., 2013). Caroline et al. discovered that
forced expression of HNF4α could reprogram pancreatic α
cell line αTC1-9 to insulin+cells (Sangan et al., 2015). More-
over, epigenetic manipulation can also facilitate α to β cell
reprogramming. Bramswig et al. treated α cells with Adox, a
histone methyltransferase inhibitor, and achieved partial con-
version to insulin+ cells (Bramswig et al., 2013). Recently it
was observed that Activin enhanced α to β cell reprogram-
ming (Brown et al., 2016), indicating that signaling regula-
tion may contribute to α to β cell reprogramming.
Pancreatic exocrine cell to β cell reprogramming
Ductal cells and acinar cells are the main cell types of pan-
creatic exocrine tissue. Acinar cells synthesize and secret
numerous digestive enzymes. In 2008, it was reported that
mouse acinar cells could be converted to β cells in vivo by
viral expression of three transcription factors (NPM factors),
Ngn3, Pdx1 andMafA (Zhou et al., 2008). This study was the
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first to confirm that β cells could be generated from mouse
pancreatic exocrine cells. Moreover, α-like and δ-like en-
docrine cells were successfully derived from mouse acinar
cells by expression of NGN3+MafAand NGN3 respectively,
which indicates that the three major islet endocrine cell types
can be generated via acinar reprogramming (Pagliuca et al.,
2014). Subsequently, β cells were induced by an improved
method, with polycistronic expression of the NPM factors,
and the long-term effects of the acinar-derived β cells were
evaluated (Li et al., 2014). It was discovered the functional β
cells could persist for up to 13 months in mice. Furthermore,
hyperglycemia was found to attenuate in vivo reprogramming
of pancreatic exocrine cells to β cells in mice (Cavelti-Weder
et al., 2016). However, whether these three transcription fac-
tors are sufficient to induce β cells from acinar cells in human
tissue is unknown.
In 2013, human ductal cells converted into β cells via
forced expression of NPM factors together with Pax6 (Lee
et al., 2013). As the PAX4-mediated α to β-like cell con-
version, pancreatic duct-lining cells can reprogram into
β-like cells which are able to mitigate diabetes (Al-Hasani
et al., 2013). Recently it was found that 2% of ductal and
acinar cells in adult human pancreas express NGN3, and
that differentiation of these NGN3+ cells could give rise to
C-peptide+/Chromogranin A+/PDX1+ endocrine cells that
resemble β cells (Gomez et al., 2015). Meanwhile, another
study described a method to convert a sub-population of
human non-endocrine pancreatic tissue to insulin-secreting
endocrine cells with a single growth factor, BMP7 (Klein et
al., 2015), thus demonstrating that transcription factor-free
methods can potentially be applied to make β cells from
pancreatic exocrine tissue. In 2016, a combination of cy-
tokines including epidermal growth factor (EGF) and ciliary
neurotrophic (CNTF) was shown to restore functional β
cell mass by reprogramming acinar cells that transiently
expressed NGN3 in mice with hyperglycaemia, which enable
development of new insights into fate re-specification of
acinar cells in diabetes (Lemper et al., 2016).
Gastrointestinal tissues to β cell reprogramming
Among endodermal tissues, the gastrointestinal epithelium is
a highly regenerative tissue harboring large numbers of adult
stem cells and progenitors that can generate hormone-se-
creting enteroendocrine cells (Drost et al., 2015; Gregorieff
and Clevers, 2015; Hoffmann, 2015; Mills and Shivdasani,
2011). For example the Lgr5+stem cells drive self-renewal in
the stomach, and can build gastric organoids in vitro (Barker
et al., 2010). In 2012 Talchai et al. generated insulin-pro-
ducing cells from gut tissue by Foxo1 ablation in Ngn3+
endocrine progenitors (Talchai et al., 2012). Subsequently
Bouchi et al. yielded functional insulin-producing cells
from human gut organoid culture through Foxo1 inhibition
(Bouchi et al., 2014), showing that intestinal tissue could
serve as a regenerative source for producing β cells. How-
ever, the deletion or suppression of Foxo1 has been shown to
cause β cell failure, possibly due to Foxo1’s ability to protect
against β cell dysfunction through the induction of NeuroD
andMafA (Kitamura et al., 2005). Thus, from the therapeutic
perspective, it may not be feasible to generate β cells by
inhibiting Foxo1. Intestinal K cells have been engineered to
produce insulin, which protect non-obese diabetic mice from
autoimmune diabetes (Mojibian et al., 2014).
In 2014, Chen et al. showed generation of “neo-β cell
islets” from intestinal crypts by knocking in NPM factors
(Chen et al., 2014) but the induced β cells lacked important
β cell markers such as NKX6.1 and prohormone convertase
2 (PC2) and exhibited limited insulin secretion upon glucose
stimulation. Thus it is crucial to generate more efficient in-
sulin-producing cells using highly regenerative tissues as a
renewable source of β cells. Recently, Ariyachet et al. re-
ported the transcriptional similarity between cells of the antral
stomach and β cells (Ariyachet et al., 2016). This study val-
idated that reprogramming stomach organoids represented a
renewable cell source that could be reprogrammed into β cells
and that were capable of rescuing hyperglycemia when trans-
planted into diabetic mice (Ariyachet et al., 2016). Com-
pared to the intestinal enteroendocrine cells, the antral en-
teroendocrine cells share more transcriptional similarity with
β cells. The induced antral insulin cells expressed key β cell
markers, including NKX6.1, NKX2.2 and PC2, which are not
expressed in the insulin-producing cells derived from intes-
tine. Moreover, the reprogrammed stomach cells included
abundant SOX9+ and Ki67+ cells, suggesting their high re-
generative capacity and potential for clinical application to
avoid repeated transplantation. Ariyachet’s study is the first
to show that NPM-engineered antral stomach could poten-
tially be used to treat diabetes.
Hepatocyte to β cell reprogramming
Liver and pancreas are believed to originate from a com-
mon precursor. The first demonstration of liver to pancre-
atic lineage reprogramming was achieved with ectopic ex-
pression of PDX1 in mice (Ferber et al., 2000). With a sim-
ilar strategy, Sapir et al. reprogrammed human adult liver
cells to insulin-producing cells in vitro, which successfully
reversed hyperglycemia after transplantation in vivo (Sapir et
al., 2005). Since then, numerous studies improved the effi-
ciency of liver to pancreas reprogramming by co-expressing
PDX1 with pancreatic transcription factors, including Neu-
roD, NGN3, MafA, and Pax4 (Ham et al., 2013; Tang et al.,
2006; Yatoh et al., 2007). The cells generated appear to re-
semble pancreatic endocrine cells that were marked by in-
sulin, glucagon and somatostatin, and were β-cell lineage. In
2010 Gefen-Halevi et al. found that co-expression of PDX1
with NKX6.1 could specifically induce liver cells into β cells
by increasing insulin production and repressing glucagon ex-
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pression (Gefen-Halevi et al., 2010). Meivar-Levy et al. fur-
ther identified that the insulin-secreting cells originated from
the human liver cells that co-expressed albumin and mes-
enchymal characteristics (Meivar-Levy et al., 2011). Qiwei
Wang et al. successfully derived pancreatic progenitor-like
cells (PPCs) from rat hepatic cells and further induced these
PPCs into pancreatic β-like cells (Wang et al., 2013). These
studies offer encouraging evidence that primary culture of
adult liver cells may possess the ability to serve as the ba-
sis for a cell replacement therapy for diabetes.
β cell regeneration by replication
Another strategy is to generate more β cells endogenously
from existing β cells. It was reported that 16% of young Type
1 diabetes patients have detectable C-peptide levels (Scholin
et al., 2004), indicating that a small number of β cells exist
in some diabetes patients, which could be potentially used as
a source for new β cells. To stimulate β cell proliferation, a
variety of small molecules have been tested and identified,
including glucagon-like peptide 1 receptor agonist (Xu et al.,
1999), cAMP-stabilizing reagents (Zhao et al., 2014), and
adenosine kinase inhibitors (Annes et al., 2012). Recently
a high-content screening system was established to identify
β-cell replication-promoting small molecules in primary cell
culture (Zhao et al., 2016). These efforts suggest that expan-
sion of endogenous β-cell might be a promising strategy to
treat diabetes.
Fibroblast to β cell reprogramming
A recent report described a newmethod to derive β cells from
fibroblasts that potentially bypasses a pluripotent reprogram-
ming step (Zhu et al., 2016). The study exploited non-integra-
tive episomal reprogramming factors, together with growth
factors and chemical compounds to generate endodermal pro-
genitor cells directly from human foreskin fibroblasts. Then
posterior foregut-like progenitors (cPF) and pancreatic endo-
dermal progenitor cells (cPE) were induced and further ex-
panded by a group of growth factors and compounds. Finally
the differentiation from cPE cells to functional pancreatic β
cells was achieved, and the induced β cells were able to lower
blood glucose level in diabetic mice. Thus, Zhu et al. dis-
covered a method for large scale production of pancreatic β
cells from fibroblasts and presented evidence that the repro-
grammed cells do not pass through a pluripotent stage. How-
ever, Bar-Nur et al. andMaza et al. argued that when somatic
cells are reprogrammed using iPSC reprogramming factors,
the majority of somatic cells must pass through a transient
pluripotent state marked by OCT4 expression and reactiva-
tion of silenced X chromosomes, suggesting that it is not en-
tirely clear whether the fibroblasts transited through a brief
pluripotent stage prior to β cell reprogramming (Bar-Nur et
al., 2015; Maza et al., 2015).
Overall, significant progress has been made in reprogram-
ming various somatic cell types to insulin+ cells. Most of
these studies were carried out in animal models. The next
major challenge is to apply these reprogramming methods to
human cells. As with all efforts to generate or regenerate β
cells, it is critical that comprehensive functional, molecular,
and epigenetic studies are carried out to thoroughly evaluate
the new β cells and compare their properties with endogenous
pancreatic β cells. Such in-depth analyses are absolutely es-
sential and have been conducted only in a small number of
cases so far.
TRANSPLANTATION AND β CELL SURVIVAL
IN VIVO
One big challenge in cell replacement therapy for Type 1 Di-
abetes is to maintain graft function in patients over the long
term after β cell transplantation. To achieve a high survival
rate and sustained glucose responsiveness of the transplanted
β cells in vivo, several major issues need to be tackled, which
include: (i) accelerating the maturation of the transplanted
cells in vivo, (ii) finding an optimal transplantation site in hu-
man body, (iii) protecting β cells from autoimmune attack and
inflammatory reactions, (iv) facilitating the vascularization of
the transplanted β cells and the insulin release from the graft.
Experimental islet transplantations have been performed in
liver, kidney capsule, spleen, omental pouch, muscle, pan-
creas, lung, stomach, subcutaneous sites, and many immuno-
privileged locations such as thymus and testes of various an-
imal models, among which kidney capsule is the major site
in diabetic mouse models (Merani et al., 2008). In human,
liver is the current transplantation site. However, intrahepatic
transplantation often results in acute or gradual graft attrition
and may lead to bleeding and thrombosis. An optimal site
for transplantation should have enough tissue volume capac-
ity and sufficient blood supply to enable the transplantation
of a large numbers of cells and maintenance of their function
in vivo. The pancreas itself is not a good transplantation site
due to the risk of pancreatitis. The intraperitoneal space and
omental pouch are potential attractive places to transplant be-
cause they can harbor large volumes of tissue and/or devices,
and blood vessels can easily form around the graft (Wahoff
et al., 1994). Intramuscular transplantation is also reason-
able owing to the comparatively easy surgical process and
the highly vascular nature of muscle (Sakata et al., 2014).
Compared to portal vein infusion and the other transplanta-
tion sites discussed above, subcutaneous transplantation is the
easiest in terms of the surgical procedure. Retrieval of the
graft is also possible under skin. In 1994, subcutaneous trans-
plantation of macro-encapsulated human islets resulted in β
cell survival and insulin secretion upon glucose stimulation
of the graft, thus providing a possible method to transplant
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β cell into the human body (Scharp et al., 1994). However,
subcutaneous islet transplants suffer from poor oxygen sup-
ply and insufficient vessel formation. The ongoing phase 1/2
clinical trial by Viacyte (NCT02239354) aims to test whether
hESC-derived pancreatic progenitors can be implanted sub-
cutaneously and maintain safely for two years in Type 1 Dia-
betes patients. Maturation of transplanted pancreatic progen-
itor cells is another critical issue. It has been reported that
chronic hyperglycemia accelerates the maturation of trans-
planted progenitor cells under the kidney capsule in mice.
In contrast, insulin treatment, anti-diabetic drug treatment, or
high-fat diets did not appear to affect the maturation in vivo
(Bruin et al., 2015c). For pancreatic progenitor cells, allow-
ing the cells to aggregate before transplantation is crucial, and
transplanted single cells fail to mature into insulin-produc-
ing cells in vivo (Beattie et al., 1996). In 2013, a Theracyte
macro-encapsulation device was adopted by Bruin et al. to
create a cell-isolation environment to protect the cells from
immune attack (Bruin et al., 2013). The important advance
of this research is that they generated the macro-encapsulated
endocrine tissue by a revised protocol, which effectively pre-
vented the progenitors from differentiating into non-pancre-
atic cell types and pancreatic exocrine tissue. Recently Bruin
et al. found that the progenitors mature faster in nude rats than
in the immunodeficient mice (Bruin et al., 2015a), which re-
veals that the recipient affects thematuration of progenitors in
vivo. Long-term glycemic control in a diabetic and immuno-
competent animal model has been achieved by encapsulat-
ing stem cell-derived β cells with alginate derivatives capa-
ble of mitigating foreign-body responses in vivo (Vegas et al.,
2016). The implants minimized the host immune responses
and maintained the glucose level without any immunosup-
pression.
Vascularization is the major factor that determines whether
the transplanted graft can respond to the glucose fluctuations
in vivo. A variety of growth factors have been added to
the transplanted graft microenvironment to stimulate angio-
genesis in the subcutaneous site. These include vascular
endothelial growth factor (VEGF), fibroblast growth factor
(FGF) and hepatocyte growth factor (HGF). Moreover,
multiple devices have been transplanted together with tis-
sues, including encapsulation devices, matrices, meshes,
hydrogels and polymers to improve the vessel formation
around the graft (Pepper et al., 2015; Zhang et al., 2013).
These biomaterials often cause inflammatory reactions that
induce macrophages to form foreign-body giant cells, which
secret signaling molecules and promote neovascularization
in the early stages but later they can induce the formation
of a collagenous fibrotic capsule around the implant that
isolates it from the host (Anderson et al., 2008). Recently
Pepper et al. developed a novel method to control this innate
foreign-body response by inducing neovascularization with
a subcutaneously transplanted hollow nylon catheter for one
month prior to islet transplantation in the device-less site
(Pepper et al., 2015). In this way, diabetes could be reversed
without a permanent encapsulation device or growth factors.
However, the transplantation should be done before the
formation of the fibrotic scar in this method, or the metabolic
exchange between the graft and the host will be hindered by
the fibrotic scar. This approach also opens up the possibility
of noninvasive imaging to monitor graft survival when ap-
plied to human while the currently used portal vein infusion
is incompatible with real-time observation.
CHALLENGES AND PERSPECTIVES
In the past 10 years multiple methods were developed to gen-
erate insulin-secreting cells that can reverse diabetes after
transplantation. These β cells provide a useful model for
anti-diabetic drug screening and toxicology testing. Many
of the published studies thus far were carried out with ani-
mal cells; it is unclear, therefore, how readily these technolo-
gies can be translated to human cells and tissues (Nair and
Hebrok, 2015). For clinical application in humans, the use of
patient-specific iPSCs as a cell source to derive β cells will en-
able avoidance of allograft rejection. Significant progress has
been made with respect to ESC- and iPSC-derived β cells, al-
though their long-term function post-transplantation needs to
be further evaluated and new methods are required to further
purify the stem cell-derived β cells to prevent formation of
cysts or tumors. For β cells derived from somatic progenitor
cells or differentiated cell types via reprogramming, a major
challenge is to deliver genetic factors with virus-free and in-
tegration-free methods to make them clinically suitable.
Another critical issue that has to be further studied is
whether transplanting pure β cells will have similar func-
tional outcomes to transplanting pancreatic tissues that
contain all types of pancreatic endocrine cells (δ, α, pp
cells), as the other islet cell types play important roles in
fine tuning β cell function and glucose regulation. Further-
more, inclusion of cell types such as the mesenchymal or
endothelial cells may facilitate long-term engraftment of
β cells in vivo (Quaranta et al., 2014). Overall, numerous
efforts have been made to generate mature and functional
β cells in vitro and in vivo. Environmental triggers and the
genetic susceptibility for diabetes could affect the efficiency
of the cell replacement therapy. Careful testing of safety
and efficacy of these approaches for diabetes is also needed.
Despite these challenges, generation of autologous human
β cells presents a very promising future for the treatment of
diabetes.
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